Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hypertension

Free Subscription Articles published in Lancet Retrieve available abstracts of 33 articles: HTML format

Single Articles

December 2022
1. KRAMER CK, Leitao CB, Viana LV
   The impact of urbanisation on the cardiometabolic health of Indigenous Brazilian peoples: a systematic review and meta-analysis, and data from the Brazilian Health registry.
   Lancet. 2022;400:2074-2083.
   PubMed     Abstract available
   
   
   November 2022
2. WEATHERALD J, Boucly A, Peters A, Montani D, et al
   The evolving landscape of pulmonary arterial hypertension clinical trials.
   Lancet. 2022;400:1884-1898.
   PubMed     Abstract available
   
   
   
3. SCHLAICH MP, Bellet M, Weber MA, Danaietash P, et al
   Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.
   Lancet. 2022 Nov 4. pii: S0140-6736(22)02034.
   PubMed     Abstract available
   
   
   
4. DECHEND R, Delles C
   Endothelin antagonists and the quest for a new therapeutic option in resistant hypertension.
   Lancet. 2022 Nov 4. pii: S0140-6736(22)02181.
   PubMed    
   
   
   October 2022
5. FANELLI E, Persu A
   SYMPLICITY HTN-3: failure at 6 months, success at 3 years?
   Lancet. 2022;400:1382-1383.
   PubMed    
   
   
   
6. SALAH HM, Mehta JL
   Best time for administration of antihypertensive medications: morning or evening?
   Lancet. 2022 Oct 11. pii: S0140-6736(22)01900.
   PubMed    
   
   
   
7. MACKENZIE IS, Rogers A, Poulter NR, Williams B, et al
   Cardiovascular outcomes in adults with hypertension with evening versus morning dosing of usual antihypertensives in the UK (TIME study): a prospective, randomised, open-label, blinded-endpoint clinical trial.
   Lancet. 2022 Oct 11. pii: S0140-6736(22)01786.
   PubMed     Abstract available
   
   
   September 2022
8. BHATT DL, Vaduganathan M, Kandzari DE, Leon MB, et al
   Long-term outcomes after catheter-based renal artery denervation for resistant hypertension: final follow-up of the randomised SYMPLICITY HTN-3 Trial.
   Lancet. 2022 Sep 16. pii: S0140-6736(22)01787.
   PubMed     Abstract available
   
   
   
9. CLAASSEN J, Park S
   Spontaneous subarachnoid haemorrhage.
   Lancet. 2022;400:846-862.
   PubMed     Abstract available
   
   
   May 2022
10. SUN Y, Mu J, Wang DW, Ouyang N, et al
    A village doctor-led multifaceted intervention for blood pressure control in rural China: an open, cluster randomised trial.
    Lancet. 2022;399:1964-1975.
    PubMed     Abstract available
    
    
    April 2022
11. FIZAZI K, Foulon S, Carles J, Roubaud G, et al
    Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design.
    Lancet. 2022;399:1695-1707.
    PubMed     Abstract available
    
    
    
12. JAFAR TH, Jabbour S
    Village doctors managing hypertension in rural China.
    Lancet. 2022 Apr 29. pii: S0140-6736(22)00424.
    PubMed    
    
    
    
13. MAHFOUD F, Kandzari DE, Kario K, Townsend RR, et al
    Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial.
    Lancet. 2022;399:1401-1410.
    PubMed     Abstract available
    
    
    
14. SARATHY H, Salman LA
    Can renal denervation replace medications for patients with hypertension?
    Lancet. 2022;399:1363-1365.
    PubMed    
    
    
    
15. WALD NJ, Law M, Morris J, Wald DS, et al
    Blood pressure meta-analysis highlights an implementation gap.
    Lancet. 2022;399:1379-1380.
    PubMed    
    
    
    November 2021
16. CAVENDER MA, Wirka RC
    Blood pressure lowering in the prevention of type 2 diabetes.
    Lancet. 2021;398:1778-1779.
    PubMed    
    
    
    
17. NAZARZADEH M, Bidel Z, Canoy D, Copland E, et al
    Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis.
    Lancet. 2021;398:1803-1810.
    PubMed     Abstract available
    
    
    
18. GARRISON SR, McCormack J
    Blood pressure treatment: how low should you go?
    Lancet. 2021;398:1684.
    PubMed    
    
    
    September 2021
19. PEARLMAN B, Lodebo BT
    Renin secreting tumour: a rare cause of secondary hypertension.
    Lancet. 2021;398:1074.
    PubMed    
    
    
    
20. KAHAN T
    Low-dose combination of blood pressure-lowering medicines.
    Lancet. 2021;398:1022-1023.
    PubMed    
    
    
    
21. NGUYEN TN, Chow CK
    Global and national high blood pressure burden and control.
    Lancet. 2021;398:932-933.
    PubMed    
    
    
    
22. JAFFAR S, Ramaiya K, Karekezi C, Sewankambo N, et al
    Controlling diabetes and hypertension in sub-Saharan Africa: lessons from HIV programmes.
    Lancet. 2021 Sep 7. pii: S0140-6736(21)01731.
    PubMed    
    
    
    August 2021
23. CHOW CK, Atkins ER, Hillis GS, Nelson MR, et al
    Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial.
    Lancet. 2021 Aug 27. pii: S0140-6736(21)01922.
    PubMed     Abstract available
    
    
    
24. JACKSON R, Wells S
    Time to remove hypertension from our vocabulary?
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01916.
    PubMed    
    
    
    
25. 
    Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis.
    Lancet. 2021 Aug 26. pii: S0140-6736(21)01921.
    PubMed     Abstract available
    
    
    
26. 
    Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants.
    Lancet. 2021 Aug 24. pii: S0140-6736(21)01330.
    PubMed     Abstract available
    
    
    July 2021
27. AFIFI T, Obeid M, Abdelati M, Almoqaid A, et al
    WHO/International Society of Hypertension risk prediction charts versus the UK Prospective Diabetes Study risk engine for cardiovascular risk assessment among patients with type 2 diabetes: a comparative study.
    Lancet. 2021;398 Suppl 1:S3.
    PubMed     Abstract available
    
    
    
28. EL-QATRAWI KJ
    Effect of hypertension on pregnancy outcomes at UNRWA health centres in Gaza governorates: a comparative study.
    Lancet. 2021;398 Suppl 1:S26.
    PubMed     Abstract available
    
    
    May 2021
29. BROUWERS S, Sudano I, Kokubo Y, Sulaica EM, et al
    Arterial hypertension.
    Lancet. 2021 May 18. pii: S0140-6736(21)00221.
    PubMed     Abstract available
    
    
    
30. AZIZI M, Sanghvi K, Saxena M, Gosse P, et al
    Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trial.
    Lancet. 2021 May 14. pii: S0140-6736(21)00788.
    PubMed     Abstract available
    
    
    
31. KAHAN T
    Decisions about antihypertensive treatment should focus on reducing cardiovascular risk.
    Lancet. 2021;397:1598-1599.
    PubMed    
    
    
    
32. 
    Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis.
    Lancet. 2021;397:1625-1636.
    PubMed     Abstract available
    
    
    March 2021
33. FIGTREE GA, Vernon ST, Hadziosmanovic N, Sundstrom J, et al
    Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data.
    Lancet. 2021;397:1085-1094.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hypertension is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: